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Edited by Jesus AvilaAbstract A monoclonal antibody speciﬁc for phosphoserines
409 and 410 of TDP-43 (mAb pS409/410) has been produced.
It strongly stained TDP-43-positive inclusions in brain of pa-
tients with frontotemporal lobar degeneration and amyotrophic
lateral sclerosis, but did not stain nuclei, in which normal
TDP-43 is localized. It did not recognize TDP-43 rapidly ex-
tracted from brains of rats at various developmental stages,
strongly suggesting that phosphorylation of Ser409/410 is an
abnormal event. Analysis of postmortem changes of TDP-43 re-
vealed that the amounts of Sarkosyl-insoluble, urea-soluble full-
length TDP-43 and a 35 kDa N-terminal fragment increased
time-dependently.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hyperphosphorylated and ubiquitinated proteins have been
identiﬁed as the major components of cytoplasmic inclusions
in a number of neurodegenerative diseases, such as tau in
tauopathies and a-synuclein in a-synucleinopathies [1,2]. Re-
cently, TAR DNA-binding protein of 43 kDa (TDP-43) was
identiﬁed as the major component of tau-negative and ubiq-
uitin-positive neuronal cytoplasmic inclusions (NCIs), intra-
nuclear inclusions and dystrophic neurites (DNs) in
frontotemporal lobar degeneration (FTLD-U), as well as
skein-like inclusions and round inclusions in amyotrophic lat-
eral sclerosis (ALS) [3–5]. TDP-43 is a protein belonging to
the group of 2 RNA-binding domain (RBD)-Gly RNA-bind-
ing proteins, which include the heterogeneous nuclear ribonu-*Corresponding author. Fax: +81 3 3329 8035.
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splicing and transport [6,7]. TDP-43 binds hnRNP A/B and
hnRNP A1 through its C-terminal region, inhibiting pre-
mRNA splicing [8]. More recently, missense mutations in
the TDP-43 gene have been identiﬁed in familial and sporadic
ALS cases [9–13]. These ﬁndings strongly suggest that struc-
tural and functional dysfunction of TDP-43 lead to aggrega-
tion of TDP-43 and neurodegeneration. Dephosphorylation
experiments indicated that the TDP-43 deposited in FTLD-
U and ALS was hyperphosphorylated [3,4]. We have raised
antibodies against 36 candidate sites for phosphorylation
and found that several antibodies against phosphopeptides
in the C-terminal region of TDP-43 strongly stained TDP-
43 lesions in FTLD-U and ALS [14]. Among these antibod-
ies, the antibody to phosphoserine 409 and 410 (pS409/410)
showed particularly robust and widespread staining of
TDP-43 lesions in FTLD-U and ALS. In addition, in vitro
phosphorylation experiments showed that the pS409/410 epi-
tope was generated by incubation of TDP-43 with casein ki-
nase (CK) 1 or CK2, and phosphorylation at these sites
increased TDP-43 oligomerization [14].
In order to investigate the phosphorylation of TDP-43 fur-
ther, we have produced and characterized a monoclonal anti-
body (mAb pS409/410) directed against phosphoserines 409
and 410 in human TDP-43. We show here that mAb
pS409/410 strongly stained all known types of TDP-43 inclu-
sions in FTLD-U and ALS, but did not stain normal TDP-
43. This mAb also stained TDP-43 phosphorylated with
CK1 or CK2 in vitro. However, it did not react with TDP-
43 rapidly extracted from brains of fetal and adult rats with
a buﬀer containing phosphatase inhibitors, though tau phos-
phorylation was detected. TDP-43 proteins were detected in
various tissues with anti-TDP-43 antibody, but not with
mAb pS409/410. These results suggest that the phosphoryla-
tion of Ser409/410 is an abnormal event that does not occur
in normal tissues. We also found that Sarkosyl-insoluble,
urea-soluble full-length TDP-43 and a 35 kDa N-terminal
fragment increased during postmortem incubation.blished by Elsevier B.V. All rights reserved.
Fig. 1. Characterization of mAb pS409/410A. (A) ELISA assay: a
synthetic peptide or phosphopeptides corresponding to residues 405–
414 of TDP-43 were probed with mAb pS409/410 antibody. (B)
Immunoblot analyses of recombinant TDP-43 phosphorylated in vitro.
Wild-type and mutated recombinant human TDP-43 were incubated
with or without CKI (10000 units/ml, NEB) in the presence of ATP at
37 C for 24 h. Immunoblots were stained with anti-TDP-43 (Protein-
Tech) and mAb pS409/410.
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2.1. Antibodies
Monoclonal antibody (mAb) pS409/410 was raised against a syn-
thetic phosphopeptide, CMDSKS(p)S(p)GWGM (amino acid residues
405–414 in human TDP43), where S(p) represents phosphoserine. The
peptide was conjugated at the amino-terminus via a cysteine linkage to
thyroglobulin from bovine thyroid, using m-maleimidobenzoyl-N-
hydroxysuccinimide ester as a coupling reagent, and the complex
was used as the immunogen. BALB/c mice were injected subcutane-
ously with 50–200 lg of peptide and boosted on days 14 and 21. The
spleen cells were removed and the cells were fused with myeloma cells
using polyethyleneglycol 4000. Screening of positive clones was per-
formed by immunohistochemistry of Triton-insoluble smears from
FTLD-U brains. Ascites were prepared by intraperitoneal injection
of cloned hybridoma cells and used in all experiments. Polyclonal anti-
body (pAb) pS409/410 and anti-TDP43C (405–414) were prepared as
described [14]. Anti-TDP-43 antibody and anti-ubiquitin antibody
were purchased from Protein Tech and Dako, respectively. Antibodies
were diluted as follows: mAb pS409/410 (1:3000–5000), pAb pS409/410
(1:2000–3000), anti-TDP-43 (1:3000–5000), anti-ubiquitin (1:2000) and
anti-TDP43C (1:1000–2000).
2.2. Preparation of recombinant TDP-43 and phosphorylation
In a full-length cDNA encoding the 414 amino acids of human TDP-
43, mutations were introduced at codons 409 (Ser to Ala: S409A), 410
(Ser to Ala: S410A), or 409 and 410 (Ser to Ala: S409A/S410A) using a
site-directed mutagenesis kit (Strategene) according to the manufac-
turers instructions. Expression and partial puriﬁcation of the wild-
type (WT) and mutated TDP-43 proteins and phosphorylation of re-
combinant TDP-43 with CK1 or CK2 were carried as described [14].
2.3. Extraction of TDP-43 and immunoblotting
Brains of embryonic 19-day (E19) and 21-day (E21), and postnatal
1-day-old (1d), 1-week-old (1w), 2-week-old (2w), 4-week-old (4w),
and 6-week-old (6w) Wistar rats were homogenized in 10 volumes of
extraction buﬀer (10 mM Tris–HCl, pH 7.5, 1 mM EGTA, 10% su-
crose, 0.8 M NaCl) containing phosphatase inhibitors (50 mM b-glyc-
erophosphate, 5 mM NaF, 5 mM NaVO3) and a protease inhibitor
cocktail (Calbiochem), and spun at 386000·g for 20 min at 4 C.
The resulting supernatants were retained as Tris-soluble fraction and
the pellets were homogenized in 10 volumes of buﬀer containing 1%
Triton X-100. The homogenates were left for 30 min at 37 C. After
a 20 min spin at 386000·g, the supernatants were retained as Triton-
soluble fraction and the pellets were homogenized in buﬀer containing
1% Sarkosyl. The homogenates were left for 30 min at 37 C, followed
by a 20 min spin at 386000·g. The supernatants were retained as
Sarkosyl-soluble fraction and the pellets were solubilized in one vol-
ume of 50 mM Tris–HCl, pH 7.5, containing 8 M urea, followed by
a 20 min spin at 386000·g. The supernatant was retained as Sarko-
syl-insoluble, urea-soluble fraction. Various tissues of 6-week-old rats
were also homogenized as described above, and the extracted proteins
were analyzed. Sarkosyl-insoluble fractions from frontal and temporal
regions of human control, FTLD-U and ALS brains were prepared as
described [14]. The samples before () and after (+) the treatment with
lambda protein phosphatase (kPPase) were loaded on 10% SDS–
PAGE. Immunoblotting was performed as described [14].
2.4. Immunohistochemistry
Human brain tissue was obtained from the Brain Donation Program
at Sun Health Research Institute, Sun City AZ and from Aichi Med-
ical University, and Tokyo Metropolitan Matsuzawa Hospital, Japan.
Small blocks of brain tissue were dissected at autopsy and frozen rap-
idly at 70 to 80 C or ﬁxed in 4% paraformaldehyde (PFA) in 0.1 M
phosphate buﬀer (pH 7.4) for 2 days. Brain tissue from patients with
sporadic FTLD-U, familial FTLD-U with PGRN mutations
(mPGRN), sporadic ALS and sporadic FTLD-MND was compared
with brain tissue from neurologically normal control subjects. Neuro-
pathological diagnoses of FTLD-U, FTLD-MND and ALS were
made in accordance with published guidelines as described [14].
Following cryoprotection in 15% sucrose in 0.01 M phosphate-buf-
fered saline (PBS) (pH 7.4), PFA-ﬁxed tissue blocks were frozen and
cut on a microtome at 30 lm thickness. Free ﬂoating sections wereimmunostained with mAb 409/410, an anti-ubiquitin antibody, and a
commercially-obtained phosphorylation-independent anti-TDP-43
antibody (ProteinTech), using reported methods [3].3. Results
3.1. Antibody speciﬁcities
To investigate the speciﬁcity of mAb pS409/410, we per-
formed ELISA assay of synthetic phospho- and non-phospho-
peptides. As shown in Fig. 1A, mAb pS409/410 strongly
reacted with a pS409/410 phosphopeptide, CMDSKS(p)S(p)
GWGM, which was used as the immunogen, but did not react
with the peptide containing non-phosphorylated S409/410. It
only weakly recognized phosphopeptides pS409 (CMDSKS(p)
SGWGM) and pS410 (CMDSKSS(p)GWGM) (Fig. 1A), sug-
gesting that this monoclonal antibody is highly speciﬁc for the
peptide phosphorylated at both Ser409 and Ser410. This was
conﬁrmed by immunoblot analysis of wild-type (WT) and mu-
tated recombinant TDP-43 before and after phosphorylation
with CK1. As shown in Fig. 1B, mAb pS409/410 failed to rec-
ognize wild-type TDP-43 prior to phosphorylation. However,
it did recognize wild-type TDP-43 that had been incubated
overnight with CK1. It also weakly recognized phosphorylated
S409A and S410A, but failed to stain S409A/S410A (Fig. 1B).
Immunoblotting with pAb pS409/410 gave similar results:
however, weak staining was detected with non-phosphorylated
Fig. 3. (A) Immunoblot analyses of the Sarkosyl-insoluble, urea-
soluble fractions from human control, FTLD-U and ALS brains with
anti-TDP-43 (ProteinTech) and mAb pS409/410 antibodies before ()
and after (+) treatment with lambda protein phosphatase (kPPase).
MAb pS409/410 speciﬁcally labels the 45 kDa full-length TDP-43, as
well as 25 kDa fragments and the smearing substances, in FTLD-U
and ALS. The labeling is abolished after dephosphorylation. Normal
43 kDa TDP-43 in control and diseased brains is not stained by mAb
pS409/410. (B) Immunoblots of the Sarkosyl-insoluble, urea-soluble
fractions from sporadic FTLD-U, FTLD-MND, ALS and mPGRN
cases with the mAb pS409/410. The samples were loaded on 15%
polyacrylamide gel. (C) Schematic diagram of the band pattern of the
C-terminal fragments of phosphorylated TDP-43.
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(data not shown), suggesting that this antiserum may not be
entirely phosphorylation-dependent.
3.2. Immunohistochemical characterization of mAb pS409/410
MAb pS409/410 strongly stained ubiquitin-positive inclu-
sions in both FTLD-U and ALS brains (Fig. 2). It recognized
NCIs in the dentate gyrus (Fig. 2A) and DNs in the temporal
cortex (Fig. 2B) of sporadic FTLD-U cases, and skein-like
inclusions (Fig. 2C), round inclusions (Fig. 2D) and glial inclu-
sions (Fig. 2E) in the spinal cord of ALS cases. These inclu-
sions were unambiguously identiﬁed by mAb pS409/410,
with no nuclear staining (Fig. 2). In some cases, pAb pS409/
410 weakly stained ghost tangles and dot-like structures in
the hippocampal region of brains from patients with AD or
other related diseases, but mAb pS409/410 did not recognize
these structures (data not shown).
3.3. Immunoreactivity of TDP-43 deposited in FTLD-U and
ALS brains and TDP-43 extracted rapidly from rat tissues
MAb pS409/410 strongly stained 45 kDa TDP-43 band,
25 kDa fragments and smearing substances in the Sarkosyl-
insoluble fractions of FTLD-U and ALS brains. Lambda pro-
tein phosphatase (kPPase) treatment of Sarkosyl-insoluble
TDP-43 resulted in loss of mAb pS409/410 immunoreactivity
(Fig. 3A). The patterns of the bands of 25 kDa fragments de-
tected with mAb 409/410 were diﬀerent between sporadic casesFig. 2. Immunohistochemistry of TDP-43 lesions. Thirty-micrometer-thick free ﬂoating sections of the dentate gyrus of hippocampus (A) and
temporal cortex (B) from FTLD-U and of spinal cords from ALS (C–E) were immunostained with mAb pS409/410. TDP-43-positive NCIs in dentate
gyrus and DNs in cortex are speciﬁcally stained. Note the absence of nuclear staining in A–E. Bars 100 lm (A,B) and 50 lm (C–E).
2902 Y. Inukai et al. / FEBS Letters 582 (2008) 2899–2904of FTLD-U, ALS and familial cases of FTLD-U with pro-
granulin mutation (Fig. 3B), as previously observed with
pAb pS409/410 [14]. Sporadic FTLD-U cases showed two ma-
jor bands at 23 and 24 kDa and two minor bands at 18 and
19 kDa, while FTLD-MND and ALS cases showed three ma-
jor bands at 23, 24 and 26 kDa and two minor bands at 18 and
19 kDa (Fig. 3B and C). The band pattern of mPGRN cases
was intermediate between those of FTLD-U, FTLD-MND
and ALS cases (Fig. 3B and C).
We next examined whether the phosphorylation of Ser409/
410 can be detected in TDP-43 rapidly extracted from fetal
or adult rats with a buﬀer containing phosphatase inhibitors,
because phosphorylation seen at many sites of tau and at
Ser129 of a-synuclein under pathological conditions is also
present in a signiﬁcant fraction of normal tau [15] or a-synuc-
lein [16], and these sites are rapidly dephosphorylated post-
mortem [17,18].
Anti-TDP-43 antibody strongly labeled the TDP-43 band at
43 kDa in Tris-soluble fractions of brains from fetal to 6-week-
old adult rats (Fig. 4A). In contrast, mAb pS409/410 failed to
detect any of the TDP-43 bands in these fractions (Fig. 4A),
though the antibody strongly stained recombinant TDP-43Fig. 4. (A) Immunoblot analyses of TDP-43 diﬀerentially extracted with Tris
developmental stages, with anti-TDP43 antibody (ProteinTech), mAb pS409/4
(Calbiochem). (B) Immunoblots of Tris-soluble extracts from various tissuesphosphorylated with CK1. On the other hand, an antibody
speciﬁc for phosphorylated tau at Ser396 (pS396) strongly rec-
ognized phosphorylated tau bands in fetal and adult rat brains
(Fig. 4B). Similar results were obtained with pAb pS409/410
(data not shown). These ﬁndings indicate that phosphorylation
of Ser409/410 does not occur in rat brain during normal devel-
opment. Immunoblot analysis of extracts from various tissues
revealed that TDP-43 is broadly expressed in various tissues
(Fig. 4C). The 43 kDa band was strongly immunostained in
cerebellum, brain stem, spinal cord, liver, lung, spleen and
ovary, but only weakly in heart and kidney (Fig. 4C). In addi-
tion to the 43 kDa band, some low-molecular bands at 30–
35 kDa in most of the tissues and a doublet at 30 kDa in kid-
ney were detected with anti-TDP-43 (Fig. 4C). In contrast, no
apparent immunoreactivity was observed with mAb pS409/
410, which was conﬁrmed to strongly immunostain recombi-
nant TDP-43 that had been phosphorylated with CK1.
3.4. Changes of TDP-43 during postmortem incubation
Rapid postmortem dephosphorylation occurs in tau and
a-synuclein, and the Cdk5 activator p35 is degraded to p25
during postmortem incubation [19]. Therefore, we investigated–HCl, Triton-X100, Sarkosyl and 8 M urea, from rat brains at various
10, an anti-tau antibody (T46: Zymed) and an anti-pS396 tau antibody
of 6-week-old rats with anti-TDP-43 and mAb pS409/410.
Fig. 5. Immunoblot analyses of brain extracts from rats after diﬀerent
postmortem intervals with anti-TDP43 antibody (ProteinTech) (A),
mAb pS409/410 (B) and anti-TDP43C (405–414) (C).
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postmortem. One-year-old rats were lethally anethetized and
the brains were excised 0, 0.5, 2, 4 or 8 h later, then homoge-
nized diﬀerentially. The extracted fractions were analyzed by
immunoblotting (Fig. 5). As shown in Fig. 5B, pS409/410
immunoreactivity was not detected in soluble or insoluble frac-
tions of the brains, nor was it generated during postmortem
incubation, indicating that phosphorylation of Ser409/410
does not occur even in aged rats. Interestingly, the levels of
Sarkosyl-insoluble and urea-soluble TDP-43 of 43 kDa as well
as Sarkosyl-soluble TDP-43 (Fig. 5A, arrowheads) and the lev-
els of urea-soluble 35 kDa fragment (Fig. 5A, arrow) gradually
increased during postmortem incubation at room temperature,
although no apparent reduction was detected in TS-soluble
TDP-43. The postmortem increase of Sarkosyl-insoluble and
urea-soluble TDP-43 was also observed with antiserum direc-
ted against the C-terminus of TDP-43 (405–414) (Fig. 5C).4. Discussion
Abnormal phosphorylation of TDP-43 has been suggested
in the initial reports that identiﬁed TDP-43 as the major com-
ponent of ubiquitin-positive inclusions in FTLD-U and ALS
[3,4]. In the present study, we have produced a monoclonal
antibody that distinguishes the disease-associated phosphory-
lation of TDP-43. By means of ELISA assay of phosphopep-
tides and a combination of site-directed mutagenesis and
in vitro phosphorylation, we have shown that mAb pS409/
410 is highly speciﬁc for TDP-43 phosphorylated at both
Ser409 and Ser410. MAb pS409/410 strongly stained TDP-
43 lesions in FTLD-U brains and ALS brains/spinal cords,
as well as abnormal TDP-43 bands and smears on immuno-
blots, in agreement with previous observations using pAbpS409/410 [14]. In contrast, mAb pS409/410 did not recognize
normal human TDP-43 of 43 kDa or TDP-43 rapidly ex-
tracted from brains of fetal to 1-year-old adult rats. It also
did not react with TDP-43 expressed in other various tissues.
These results indicate that phosphorylation of TDP-43 at
Ser409/410 is a pathological event. This is diﬀerent from
the cases of tau or a-synuclein, where phosphorylation at
most of the sites can be detected in normal fetal or adult
brain. It remains unknown whether the abnormal phosphor-
ylation of TDP-43 at Ser409/410 precedes assembly of TDP-
43, or whether it is a reaction associated with aggregation or
conformational change of TDP-43. However, it is clear that
the phosphorylation is a speciﬁc biological marker for detec-
tion of abnormal TDP-43 deposits in FTLD-U and ALS
brains/spinal cords.
In the course of characterization of mAb pS409/410, we
found that the levels of Sarkosyl-insoluble and urea-soluble
TDP-43 increased during postmortem incubation. A similar
increase of Sarkosyl-insoluble TDP-43 was observed during
the incubation of recombinant human TDP-43 at 37 C for
24 h (data not shown). These results suggest that the
sarkosyl-insoluble, urea-soluble TDP-43 of 43 kDa and the
35 kDa fragment detected in brains of human controls and pa-
tients with FTLD-U or ALS may have been artifacts generated
postmortem. Zhang et al. reported that the amounts of the 35
and 25 kDa fragments were increased in cells treated with stau-
rosporin or PGRN siRNA and in brains of patients of FTLD-
U [20], whereas Shankaran found that these fragments of
TDP-43 were generated independently of PGRN knock-down
in cell lines and zebraﬁsh [21]. Our results show that a 35 kDa
N-terminal fragment of TDP-43 is generated during postmor-
tem incubation and recovered in insoluble fractions, but this is
irrelevant to the pathology of TDP-43 proteinopathy.
As had been found with pAb pS409/410, mAb pS409/410 re-
vealed that the 18–26 kDa C-terminal fragments of TDP-43
are the major species of TDP-43 deposited in patients with
FTLD-U and ALS, and the patterns of the fragments are clo-
sely related to the neuropathological subtypes of the inclu-
sions. Although further studies are needed to clarify the
molecular mechanisms of the fragmentation and aggregation
of TDP-43, the results presented here suggest that aggregation
of TDP-43 is implicated in FTLD-U and ALS, just as aggrega-
tion and phosphorylation of tau or a-synuclein may be in-
volved in other neurodegenerative diseases. MAb pS409/410
may be a useful probe for detection of abnormal TDP-43 in tis-
sues of patients and for evaluation of cellular or animal models
of TDP-43 proteinopathy. Antibodies speciﬁc for the abnor-
mal phosphorylation sites of TDP-43 may be useful for anti-
body therapy, or the antigens may be suitable for
immunization against FTLD-U and ALS.References
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